Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension

American Journal of Hypertension

Volumn 22, Issue 7, 2009, Pages 748-753

  Pacanowski, Michael A ^a   Zineh, Issam ^a,b   Cooper Dehoff, Rhonda M ^b   Pepine, Carl J ^b   Johnson, Julie A ^a,b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROCHLOROTHIAZIDE; TRANDOLAPRIL; VERAPAMIL;

AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DNA POLYMORPHISM; DRUG DOSE TITRATION; FEMALE; GENETIC ASSOCIATION; HEART INFARCTION; HUMAN; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE;

AGED; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BLOOD PRESSURE; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; PHARMACOGENETICS; VERAPAMIL;

EID: 67649354432     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2009.81     Document Type: Article

References (24)

1. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006; 113:1708-1714.
2. Iwai C, Akita H, Kanazawa K, Shiga N, Terashima M, Matsuda Y, Takai E, Miyamoto Y, Shimizu M, Kajiya T, Hayashi T, Yokoyama M. Arg389Gly polymorphism of the human beta1-adrenergic receptor in patients with nonfatal acute myocardial infarction. Am Heart J 2003; 146:106-109.
3. Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Kugiyama K, Ogawa H, Motoyama T, Saito Y, Ogawa Y, Miyamoto Y, Nakao K. T-786->C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999; 99:2864-2870.
4. Cattaruzza M, Guzik TJ, Slodowski W, Pelvan A, Becker J, Halle M, Buchwald AB, Channon KM, Hecker M. Shear stress insensitivity of endothelial nitric oxidesynthase expression as a genetic risk factor for coronary heart disease. Circ Res 2004; 95:841-847.
5. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci USA 2000; 97:2832-2835.
6. Persu A, Stoenoiu MS, Messiaen T, Davila S, Robino C, El-Khattabi O, Mourad M, Horie S, Feron O, Balligand JL, Wattiez R, Pirson Y, Chauveau D, Lens XM, Devuyst O. Modifier effect of ENOS in autosomal dominant polycystic kidney disease. Hum Mol Genet 2002; 11:229-241.
7. Savvidou MD, Vallance PJ, Nicolaides KH, Hingorani AD. Endothelial nitric oxide synthase gene polymorphism and maternal vascular adaptation to pregnancy. Hypertension 2001; 38:1289-1293.
8. Leeson CP, Hingorani AD, Mullen MJ, Jeerooburkhan N, Kattenhorn M, Cole TJ, Muller DP, Lucas A, Humphries SE, Deanfield JE. Glu298Asp endothelial nitric oxide synthase gene polymorphism interacts with environmental and dietary factors to influence endothelial function. Circ Res 2002; 90:1153-1158.
9. Casas JP, Cavalleri GL, Bautista LE, Smeeth L, Humphries SE, Hingorani AD. Endothelial nitric oxide synthase gene polymorphisms and cardiovascular disease: a HuGE review. Am J Epidemiol 2006; 164:921-935.
10. Zintzaras E, Kitsios G, Stefanidis I. Endothelial NO synthase gene polymorphisms and hypertension: a meta-analysis. Hypertension 2006; 48:700-710.
11. Ignarro LJ, Napoli C, Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 2002; 90:21-28.
12. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805-2816.
13. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265.
14. Lee CR, North KE, Bray MS, Avery CL, Mosher MJ, Couper DJ, Coresh J, Folsom AR, Boerwinkle E, Heiss G, Zeldin DC. NOS3 polymorphisms, cigarette smoking, and cardiovascular disease risk: the Atherosclerosis Risk in Communities study. Pharmacogenet Genomics 2006; 16:891-899.
15. Johnson JA. Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics. Circulation 2008; 118:1383-1393.
16. Turner ST, Chapman AB, Schwartz GL, Boerwinkle E. Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens 2003; 16: 834-839.
17. Arnett DK, Claas SA, Glasser SP. Pharmacogenetics of antihypertensive treatment. Vascul Pharmacol 2006; 44:107-118.
18. Rossi GP, Taddei S, Virdis A, Cavallin M, Ghiadoni L, Favilla S, Versari D, Sudano I, Pessina AC, Salvetti A. The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. J Am Coll Cardiol 2003; 41:938-945.
19. Pasini AF, Garbin U, Stranieri C, Boccioletti V, Mozzini C, Manfro S, Pasini A, Cominacini M, Cominacini L. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens 2008; 21:1251-1257.
20. Fratta Pasini A, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura T, Lo Cascio V, Cominacini L. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005; 23:589-596.
21. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The National High Blood Pressure Education Program Coordinating C. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
22. Pereira TV, Rudnicki M, Cheung BM, Baum L, Yamada Y, Oliveira PS, Pereira AC, Krieger JE. Three endothelial nitric oxide (NOS3) gene polymorphisms in hypertensive and normotensive individuals: meta-analysis of 53 studies reveals evidence of publication bias. J Hypertens 2007; 25:1763-1774.
23. Agema WR, de Maat MP, Zwinderman AH, Kastelein JJ, Rabelink TJ, van Boven AJ, Feskens EJ, Boer JM, van der Wall EE, Jukema JW. An integrated evaluation of endothelial constitutive nitric oxide synthase polymorphisms and coronary artery disease in men. Clin Sci 2004; 107:255-261.
24. Morgan TM, Krumholz HM, Lifton RP, Spertus JA. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA 2007; 297:1551-1561.